|
gptkbp:instanceOf
|
monoclonal antibody
|
|
gptkbp:activeDuring
|
gptkb:Avelumab
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:chemicalFormula
|
C646H1008N174O198S4
|
|
gptkbp:clinicalTrials
|
Phase 1
oncology
Phase 2
Phase 3
ASCO guidelines
ESMO guidelines
JAVELIN Bladder 100
JAVELIN Merkel 200
JAVELIN Solid Tumor
NCCN_guidelines
|
|
gptkbp:contraindication
|
hypersensitivity to avelumab
immune-mediated adverse reactions
|
|
gptkbp:developedBy
|
Merck KGaA
|
|
gptkbp:drugInterdiction
|
immunotherapy
|
|
gptkbp:expirationDate
|
24 months
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bavencio
|
|
gptkbp:isATypeOf
|
1432020-66-0
|
|
gptkbp:issuedBy
|
healthcare_professional
|
|
gptkbp:lastProduced
|
2017
|
|
gptkbp:mandates
|
advanced cancer
|
|
gptkbp:marketedAs
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
gptkb:Bavencio
|
|
gptkbp:operates_in
|
L01XC17
|
|
gptkbp:packaging
|
vial
|
|
gptkbp:patentStatus
|
patented
|
|
gptkbp:researchFocus
|
cancer immunotherapy
|
|
gptkbp:researchInterest
|
gptkb:AstraZeneca
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Roche
gptkb:Eisai
|
|
gptkbp:route
|
intravenous
|
|
gptkbp:sells
|
gptkb:Bavencio
|
|
gptkbp:sideEffect
|
fatigue
nausea
diarrhea
rash
infusion-related reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:supplyChain
|
solution for infusion
|
|
gptkbp:targets
|
gptkb:PD-L1
|
|
gptkbp:triggerType
|
PD-L1_inhibitor
|
|
gptkbp:usedFor
|
treatment of urothelial carcinoma
treatment_of_Merkel_cell_carcinoma
|